1. Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to
2018
Published: November 2011
No. of Pages: 87
Price: $ 3500
GlobalData, the industry analysis specialist, has released its new report, “Brain Hemorrhage
Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an
essential source of information and analysis on the global brain hemorrhage therapeutics
market. The report identifies the key trends shaping and driving the global brain
hemorrhage therapeutics market. The report also provides insights on the prevalent
competitive landscape and the emerging players expected to significantly alter the market
positioning of the current market leaders. Most importantly, the report provides valuable
insights on the pipeline products within the global brain hemorrhage sector. This report is
built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global brain hemorrhage therapeutics market was valued at
$358m in 2010 and forecasts to grow at a Compound Annual Growth Rate (CAGR) of 3%
over the next eight years, to reach $452m by 2018. The slow growth in the brain
hemorrhage therapeutics market is largely due to the stable prevalence, high mortality and
weak pipeline with only two company sponsored drugs in the pipeline. Life style factors such
as smoking, obesity and alcohol are the major risk factors associated with brain
hemorrhage. The existing market does not have any approved therapies and the off-label
drugs such as antihypertensive agents (labetalol and nicardipine), hemostatic agents
(vitamin K and rfVIIa), antiepileptic drugs (phenytoin and lorazepam) and osmotherapy
(mannitol 20%) are the most commonly prescribed therapies. These treatment options offer
symptomatic treatment. These drugs/ therapies lack superior safety and efficacy. These
factors would result in slow growth of the global brain hemorrhage therapeutics market
through 2018.
GlobalData has found that the brain hemorrhage therapeutics market has high unmet
needs, suggesting that the current market is not well served by the current treatment
options. Moreover, these treatment options are not approved and are used as off-label. The
market is dominated by off-label and generic medications which include antihypertensive
agents, hemostatic agents, antiepileptic agents, and osmotherapy. Absence of approved
therapies for brain hemorrhage clearly establishes that the current brain hemorrhage

2. therapeutics market has high unmet need and there is scope for new entrants exhibiting
superior safety and efficacy
Scope
The report provides information on the key drivers and challenges of the brain hemorrhage
therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan)
brain hemorrhage market revenues data from 2005 to 2010, forecast for eight years to
2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action
being developed and emerging trends. Most of the clinical trials are conducted by academic
institutions, currently only GLP-1 CellBeads and PG2 are the drugs sponsored by CellMed
AG/BTG and PhytoHealth Corporation respectively. Of the total number drugs in the
pipeline, four drugs are first-in-class and the remaining 12 drugs are generics. The
mechanism of action of one drug in phase 0 is unknown. The first-in-class molecules have a
distinct advantage over the currently marketed products with regards to better symptomatic
management.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization,
unmet needs and the implications for the brain hemorrhage therapeutics market.
- Analysis of key recent licensing and partnership agreements in brain hemorrhage
therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of
pipeline products and technologies and by identifying the companies with the most robust
pipeline.
- Develop business strategies by understanding the trends shaping and driving the global
brain hemorrhage therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies,
market segments and companies likely to impact the global brain hemorrhage therapeutics
market in future.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.

3. - Organize your sales and marketing efforts by identifying the market categories and
segments that present maximum opportunities for consolidations, investments and strategic
partnerships.
- What’s the next big thing in the global brain hemorrhage therapeutics market landscape?
– Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 7
2 Brain Hemorrhage Therapeutics: Executive Summary 10
2.1 The Brain Hemorrhage Therapeutics Market is Forecast to Show Slow Growth until 2018
10
2.2 Weak Pipeline Candidates Likely to Result in Slow Growth through 2018 11
2.3 High Unmet Need Continues to Challenge the Pipeline Drugs Market 12
3 Brain Hemorrhage Therapeutics: Introduction 13
3.1 Overview 13
3.1.1 Diagnostic and Statistical Manual of Cerebrovasculer diseases- Classification for
Stroke: 14
3.1.2 Definition of Stroke by WHO 15
3.1.2.1 Stroke 15
3.1.2.2 Hemorrhagic Stroke 15
3.1.3 Quality of Life 16
3.2 Epidemiology 17
3.2.1 Worldwide Prevalence 17
3.2.2 Incidence of Cerebral Hemorrhage 17
3.2.2.1 Worldwide incidence 17
3.2.2.2 The US 17
3.2.2.3 EU 5 17
3.2.2.4 Japan 18
3.2.3 Mortality Rate 18
3.2.3.1 The US 18
3.2.3.2 EU 5 18
3.2.4 Epidemiology Trends 18
3.2.5 Age, Gender & Ethnicity 19
3.2.6 Economic burden 19
3.3 Etiology and Pathophysiology 22
3.3.1 ICH 22
3.3.2 SAH 23
3.3.3 Risk Factors 24
3.3.3.1 Controllable or treatable risk factors 24
3.3.3.2 Uncontrollable risk factors include: 25
3.4 Signs and Symptoms 26
3.4.1 The Face Arm Speech Test 28
3.5 Diagnosis 28
3.5.1 Other Tests 29
3.5.2 The Glasgow Coma Scale 29
3.5.3 Referral pathway 31
3.6 Treatment and Management 31

4. 3.6.1 Emergency management 33
3.6.2 Prevention 36
3.6.2.1 Primary prevention 36
3.6.2.2 Secondary prevention 36
3.6.3 Rehabilitation 37
3.6.3.1 Rehabilitation during acute phase 37
3.6.3.2 Post stroke rehabilitation 38
3.7 GlobalData Pipeline Report Guidance 38
4 Brain HemorrhageTherapeutics: Market Characterization 39
4.1 Overview 39
4.2 Brain Hemorrhage Therapeutics Market Size (2005–2010) – Global 39
4.3 Brain HemorrhageTherapeutics Market Forecast (2010-2018) – Global 41
4.4 Brain Hemorrhage Therapeutics Market Size (2005-2010) –The US 42
4.5 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) – The US 43
4.6 Brain Hemorrhage Therapeutics Market Size (2005-2010) – France 44
4.7 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) – France 45
4.8 Brain Hemorrhage Therapeutics Market Size (2005-2010) – Germany 46
4.9 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) – Germany 47
4.10 Brain Hemorrhage Therapeutics Market Size (2005-2010) – Italy 48
4.11 Brain Hemorrhage Therapeutics Market forecast (2010-2018) – Italy 49
4.12 Brain Hemorrhage Therapeutics Market Size (2005-2010) – Spain 50
4.13 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) – Spain 51
4.14 Brain Hemorrhage Therapeutics Market Size (2005-2010) – The UK 52
4.15 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) – The UK 53
4.16 Brain Hemorrhage Therapeutics Market Size (2005-2010) – Japan 54
4.17 Brain Hemorrhage Therapeutics Market Forecast (2010-2018) – Japan 55
4.18 Drivers and Barriers for the Brain Hemorrhage Therapeutics Market 56
4.18.1 Drivers for the Brain Hemorrhage Therapeutics Market 56
4.18.1.1 Risk factors 56
4.18.1.2 High treatment and diagnosis rate 56
4.18.2 Barriers for the Brain Hemorrhage Therapeutic Market 56
4.18.2.1 Off-label usage 56
4.18.2.2 High mortality rate 56
4.19 Opportunity and Unmet Need 57
4.20 Key Takeaway 57
5 Brain HemorrhageTherapeutics: Competitive Assessment 58
5.1 Overview 58
5.2 Strategic Competitor Assessment 58
5.3 Product Profiles for the Major Off-Label Marketed Products in the Brain Hemorrhage
Market 59
5.3.1 Antihypertensive 59
5.3.1.1 Overview 59
5.3.1.2 Clinical Studies 60
5.3.1.3 Annual Cost of Therapy 60
5.3.2 Hemostatic Therapy 60
5.3.2.1 Overview 60
5.3.2.2 Clinical Studies 61
5.3.2.3 Annual Cost of Therapy 62
5.3.3 Antiepileptic drugs 62
5.3.3.1 Overview 62

5. 5.3.3.2 Clinical Studies 62
5.3.3.3 Annual Cost of Therapy 62
5.3.4 Osmotherapy 62
5.3.4.1 Overview 62
5.3.4.2 Clinical Studies 63
5.3.4.3 Annual Cost of Therapy 63
5.4 Key Takeaway 63
6 Brain Hemorrhage Therapeutics - Pipeline Assessment 63
6.1 Overview 63
6.2 Strategic Pipeline Assessment 64
6.3 Brain Hemorrhage Therapeutics Pipeline – Pipeline by Phases of Development 64
6.3.1 Brain Hemorrhage Therapeutics – Phase III and NDA Filled Pipeline 64
6.3.2 Brain Hemorrhage Therapeutics – Phase II Pipeline 65
6.3.3 Brain Hemorrhage Therapeutics – Phase I/II Pipeline 65
6.3.4 Brain Hemorrhage Therapeutics –Phase I Pipeline 65
6.3.5 Brain Hemorrhage Therapeutics –Phase 0 Pipeline 66
6.4 Brain Hemorrhage Therapeutics Market – Pipeline by Mechanism of action 66
6.5 Technology Trends Analytical Framework 67
6.6 Brain Hemorrhage Therapeutics – Promising Drugs Under Development 69
6.7 Molecule Profile for Promising Drugs Under Development 70
6.7.1 GLP-1 CellBeads 70
6.7.1.1 Overview 70
6.7.1.2 Efficacy 70
6.7.1.3 Safety 70
6.7.1.4 Clinical Study Details 70
6.8 Key Takeaway 70
7 Brain Hemorrhage Therapeutics - Clinical Trials Mapping 71
7.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 71
7.2 Clinical Trials by Phase 72
7.3 Clinical Trials by Trial Status 73
7.4 Prominent Sponsors 74
7.5 Top Companies Participating in Brain Hemorrhage Therapeutics Clinical Trials 75
8 Brain HemorrhageTherapeutics: Strategic Assessment 76
8.1 Key Events Impacting the Future Market 76
8.2 Future Market Competition Scenario 77
9 Brain HemorrhageTherapeutics: Future Players 78
9.1 Introduction 78
9.2 BTG 78
9.2.1 Company Overview 78
9.2.2 Financial Overview 79
9.2.3 Business Description 79
9.2.4 Brain Hemorrhage Therapeutics Pipeline 80
10 Brain Hemorrhage Therapeutics Market: Appendix 80
10.1 Market Definitions 80
10.2 Abbreviations 81
10.3 Research Methodology 81
10.3.1 Coverage 82
10.3.2 Secondary Research 82
10.3.3 Forecasting 82
10.3.4 Primary Research 85

6. 10.3.5 Expert Panels 86
10.4 Contact Us 86
10.5 Disclaimer 86
10.6 Bibliography 87
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog